Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19.

Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID-19.

Publication date: Oct 01, 2024

Nicotinamide adenine dinucleotide (NAD) depletion has been postulated as a contributor to the severity of COVID-19; however, no study has prospectively characterized NAD and its metabolites in relation to disease severity in patients with COVID-19. We measured NAD and its metabolites in 56 hospitalized patients with COVID-19 and in two control groups without COVID-19: (1) 31 age- and sex-matched adults with comorbidities, and (2) 30 adults without comorbidities. Blood NAD concentrations in COVID-19 group were only slightly lower than in the control groups (p 

Concepts Keywords
Depletion 1‐methylnicotinamide
Dinucleotide 2PY
Hospitalized NAD+ metabolites
Sex NAD+ turnover
nicotinamide
SARS‐CoV‐2 infection

Semantics

Type Source Name
drug DRUGBANK Nadide
disease MESH COVID-19
disease IDO blood
disease MESH Long Covid
drug DRUGBANK Nicotinamide
disease MESH infection

Original Article

(Visited 2 times, 1 visits today)